<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02965118</url>
  </required_header>
  <id_info>
    <org_study_id>CAPTAIN-AD-301</org_study_id>
    <nct_id>NCT02965118</nct_id>
  </id_info>
  <brief_title>CAPTAIN-AD: Clinical Study of AmorePacific's TRPV1 Antagonist in Atopic Dermatitis</brief_title>
  <official_title>Multi Center, Randomized, Double-blind, Placebo-controlled Parallel-group, Phase III Clinical Trial to Evaluate the Safety and Efficacy of PAC-14028 Cream in Mild to Moderate Atopic Dermatitis Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Amorepacific Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Amorepacific Corporation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase III study to investigate the safety and efficacy of PAC-14028 cream in Atopic
      Dermatitis patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PAC-14028 cream 1.0% or placebo will be treated to Mild to Moderate Atopic Dermatitis
      patients twice daily for 8 weeks.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2016</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">August 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Success rate of Investigator's Global Assessment (IGA)</measure>
    <time_frame>8 weeks</time_frame>
    <description>Percent of patients with IGA score of 0 (clear) or 1 (almost clear)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change of Investigator's Global Assessment (IGA) score</measure>
    <time_frame>8 weeks</time_frame>
    <description>Change of IGA score from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Success rate of ≥2-grade Investigator's Global Assessment (IGA)</measure>
    <time_frame>8 weeks</time_frame>
    <description>percent of patients with ≥2 grade reduction of IGA score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of change in Eczema Area and Severity Index (EASI)</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">240</enrollment>
  <condition>Atopic Dermatitis</condition>
  <arm_group>
    <arm_group_label>PAC-14028 cream 1.0%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PAC-14028 cream 1.0% will be applied to treatment area twice daily for 8 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PAC-14028 cream Vehicle</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>PAC-14028 cream Vehicle will be applied to treatment area twice daily for 8 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PAC-14028 cream 1.0%</intervention_name>
    <description>topical application</description>
    <arm_group_label>PAC-14028 cream 1.0%</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PAC-14028 cream Vehicle</intervention_name>
    <description>topical application</description>
    <arm_group_label>PAC-14028 cream Vehicle</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and female patients aged 12 - 70 years.

          -  Who was diagnosed with Atopic Dermatitis according to Haniffin and Rajka criteria.

          -  Whose affected TBSA is over 5% and below 30%, and IGA score is 2 (mild) to 3
             (moderate).

          -  Who voluntarily agreed to participate in the study and signed an informed consent
             form.

        Exclusion Criteria:

          -  Who has skin diseases other than atopic dermatitis or scar in the affected area which
             can affect the study, determined by the study investigators.

          -  Who has clinically significant medical history or diseases involving liver, kidney,
             neurological system, psychical disorder that can affect study results.

          -  Who has used systemic steroids, antibiotics, immunosuppressants, or received
             phototherapy within 28 days before study drug administration.

          -  Who has used topical steroids, topical calcineurin inhibitors or antibiotics to treat
             atopic dermatitis within 14 days before study drug administration.

          -  Who has used or is expected to inevitably use prohibited concomitant medications
             during the study.

          -  Women who is pregnant /breast-feeding, or who has childbearing potential and does not
             use available contraceptives.

          -  Who has dosed other study medications within 30 days before screening.

          -  Who is determined ineligible for study participation by investigators for any other
             reasons.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kyuhan Kim, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Miyoung Park, PhD</last_name>
    <phone>82312805927</phone>
    <email>mypark@amorepacific.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Gyeyoung Choi, MS</last_name>
    <phone>82312805936</phone>
    <email>gyeyoungchoi@amorepacific.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kyuhan Kim, MD, PhD</last_name>
      <phone>82220723643</phone>
      <email>kyuhkim@snu.ac.kr</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 14, 2016</study_first_submitted>
  <study_first_submitted_qc>November 14, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 16, 2016</study_first_posted>
  <last_update_submitted>November 27, 2016</last_update_submitted>
  <last_update_submitted_qc>November 27, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 29, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dermatitis</mesh_term>
    <mesh_term>Dermatitis, Atopic</mesh_term>
    <mesh_term>Eczema</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

